Dr. Abreo

About Dr. Abreo

Dr. Abreo has over 30 years of experience in the US pharmaceutical industry having commenced his a career in medicinal chemistry in neuroscience at Abbott Labs & worked at other top tier pharma companies post his tenure at Abbott. He held leadership positions within these organizations with increasing levels of responsibilities. He has made key contributions to several different drug-discovery and development programs, inclusive of scale-up and manufacturing (cGMP) campaigns, formulation development, pre-clinical and clinical development in diverse therapeutic areas such as CNS (central nervous system), oncology, virology, CV (cardio-vascular), diabetes and obesity (Metabolic Syndrome), pain and radiation sickness all leading to successful outcomes. His noteworthy contributions in virology include hCMV (human cytomegalovirus) and HCV (Hepatitis C “see https://en.wikipedia.org/wiki/Filibuvir”). He was a member of the leadership team of Ph.D. scientists tasked at evaluating potential HIV (human immunodeficiency virus) candidates from the computational screening of virtual libraries to prioritize candidates for high throughput synthesis and testing. He continues research in virology and is focused on HSV-1 & HSV-2 (herpes simplex virus 1 & 2), shingles, and other infectious disease enveloped viruses. Dr. Abreo is also involved in the CoVID-19 (aka SARS-CoV-2) initiative. He is a named inventor and author on numerous patents and several publications. He serves as a consultant to small virtual biotech companies. He has also facilitated and closed several high-value business deals and performed scientific due diligence for mergers and acquisitions transactions. He is the primary inventor/entrepreneur of TriClara’s intellectual property. He holds a Ph.D. in chemistry from the University of California, Davis, and completed his post-doctoral training at the University of Rochester, New York.